Schonfeld Strategic Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-275,000	Closed	-$27.6M	–	2662
2025 Q3	$27.6M	Buy	+275,000	New	+$24.8M	0.16%	122
2024 Q3	–	Sell	-300,000	Closed	-$27.8M	–	2472
2024 Q2	$27.8M	Buy	+300,000	New	+$26.9M	0.18%	107
2024 Q1	–	Sell	-600,000	Closed	-$53.6M	–	2456
2023 Q4	$53.6M	Hold	600,000	–	–	0.36%	28
2023 Q3	$43.8M	Hold	600,000	–	–	0.34%	48
2023 Q2	$1.52M	Buy	+600,000	New	+$50.2M	0.01%	850
2022 Q1	–	Sell	-50,000	Closed	-$5.6M	–	2961
2021 Q4	$5.6M	Sell	50,000 -50,000	-50%	-$6.03M	0.05%	431
2021 Q3	$12.6M	Buy	+100,000	New	+$12.9M	0.13%	206

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Schonfeld Strategic Advisors's XBI Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 7,643 shares worth $976K. The stake represents 0.01% of the portfolio and ranks #1107 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in XBI as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in XBI in Q3 2020 and has held it in 19 quarters since. The position peaked at $31M in Q2 2023. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Schonfeld Strategic Advisors held 7,643 shares of State Street SPDR S&P Biotech ETF worth $976K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new Schonfeld Strategic Advisors position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1107 holding.
Schonfeld Strategic Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 19 quarters since.
Schonfeld Strategic Advisors's State Street SPDR S&P Biotech ETF position peaked at $31M in Q2 2023.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.